The exposure of interest was concomitant oral antidepressants while taking linezolid that were known to predispose patients to serotonin syndrome as per the FDA
To characterize the post-marketing reporting of serotonin syndrome (SS) due to drug-drug interactions (DDIs) with linezolid and investigate the relationship with
Purpose: Linezolid is a monoamine oxidase inhibitor that may increase the risk of serotonin syndrome in patients receiving combination selective serotonin reuptake
Methods This was a retrospective observational